NASDAQ:WVE Wave Life Sciences (WVE) Stock Forecast, Price & News $4.13 -0.13 (-3.05%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$4.13▼$4.3450-Day Range$3.56▼$4.6952-Week Range$1.86▼$7.12Volume372,413 shsAverage Volume388,957 shsMarket Capitalization$406.27 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Wave Life Sciences MarketRank™ ForecastAnalyst RatingHold2.40 Rating ScoreUpside/Downside69.5% Upside$7.00 Price TargetShort InterestBearish2.25% of Shares Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.32) to ($1.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 starsMedical Sector370th out of 982 stocksPharmaceutical Preparations Industry169th out of 470 stocks 3.2 Analyst's Opinion Consensus RatingWave Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Wave Life Sciences has a forecasted upside of 69.5% from its current price of $4.13.Amount of Analyst CoverageWave Life Sciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.25% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Wave Life Sciences has recently increased by 13.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreWave Life Sciences has received a 74.56% net impact score from Upright. Wave Life Sciences seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Taxes". The positive contribution in the "Physical diseases" impact category is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Wave Life Sciences is -0.57. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders32.20% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.18% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Wave Life Sciences are expected to grow in the coming year, from ($1.32) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Wave Life Sciences (NASDAQ:WVE) StockWave Life Sciences Ltd. is a clinical-stage genetic medicines company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, optimization, and production of novel stereopure oligonucleotides. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.Read More Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address WVE Stock News HeadlinesMay 28, 2023 | americanbankingnews.comWave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Rating of "Moderate Buy" from BrokeragesMay 28, 2023 | americanbankingnews.comFY2024 Earnings Estimate for Wave Life Sciences Ltd. Issued By SVB Leerink (NASDAQ:WVE)June 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 26, 2023 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Price Target Cut to $10.00 by Analysts at MizuhoMay 26, 2023 | americanbankingnews.comJefferies Financial Group Downgrades Wave Life Sciences (NASDAQ:WVE) to HoldMay 24, 2023 | msn.comMizuho Maintains Wave Life Sciences (WVE) Buy RecommendationMay 24, 2023 | msn.comHC Wainwright & Co. Reiterates Wave Life Sciences (WVE) Buy RecommendationMay 23, 2023 | msn.comWave Life Sciences Notches Higher despite Drug Trial SetbackJune 7, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!May 23, 2023 | markets.businessinsider.comWave Life Sciences (WVE) Gets a Buy from Mizuho SecuritiesMay 23, 2023 | benzinga.comWave Life Sciences shares are trading lower after the company announced WVE-004 did not show clinical benefit compared with the placebo.May 23, 2023 | marketwatch.comWave Life Sciences Ends Development of WVE-004 to Treat Lou Gehrig's Disease, DementiaMay 23, 2023 | finance.yahoo.comWave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal DementiaMay 19, 2023 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Receives New Coverage from Analysts at StockNews.comMay 16, 2023 | finance.yahoo.comWave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual MeetingMay 10, 2023 | americanbankingnews.comSVB Leerink Comments on Wave Life Sciences Ltd.'s Q2 2023 Earnings (NASDAQ:WVE)May 9, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Wave Life Sciences Ltd. Boosted by Analyst (NASDAQ:WVE)May 8, 2023 | finance.yahoo.comThe Consensus EPS Estimates For Wave Life Sciences Ltd. (NASDAQ:WVE) Just Fell DramaticallyMay 7, 2023 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Upgraded at StockNews.comMay 5, 2023 | finance.yahoo.comWave Life Sciences First Quarter 2023 Earnings: Misses ExpectationsMay 3, 2023 | finance.yahoo.comWave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 26, 2023 | finance.yahoo.comWave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023April 20, 2023 | finance.yahoo.comWave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform ChemistryApril 18, 2023 | americanbankingnews.comWave Life Sciences Ltd. (NASDAQ:WVE) Short Interest Up 32.0% in MarchApril 14, 2023 | msn.comMizuho Reiterates Wave Life Sciences (WVE) Buy RecommendationApril 13, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Wave Life Sciences (WVE)March 31, 2023 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Upgraded to "Hold" by StockNews.comSee More Headlines WVE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WVE Company Calendar Last Earnings3/22/2023Today6/07/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:WVE CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees235Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+67.9%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,820,000.00 Net Margins-1,021.14% Pretax Margin-1,016.54% Return on Equity-1,038.84% Return on Assets-74.91% Debt Debt-to-Equity RatioN/A Current Ratio1.66 Quick Ratio1.66 Sales & Book Value Annual Sales$3.65 million Price / Sales112.38 Cash FlowN/A Price / Cash FlowN/A Book Value($0.52) per share Price / Book-8.02Miscellaneous Outstanding Shares98,370,000Free Float66,696,000Market Cap$410.20 million OptionableOptionable Beta-0.90 Key ExecutivesPaul B. BolnoPresident, Chief Executive Officer & DirectorKyle MoranChief Financial OfficerChandra VargeeseChief Technology OfficerChristopher FrancisSVP-Corporate Development & Head-Emerging AreasAnne-Marie Li-Kwai-CheungChief Development OfficerKey CompetitorsscPharmaceuticalsNASDAQ:SCPHTheseus PharmaceuticalsNASDAQ:THRXAllakosNASDAQ:ALLKIGM BiosciencesNASDAQ:IGMSArbutus BiopharmaNASDAQ:ABUSView All CompetitorsInsiders & InstitutionsGeode Capital Management LLCBought 27,438 shares on 5/16/2023Ownership: 0.704%Jane Street Group LLCBought 268,454 shares on 5/16/2023Ownership: 0.379%State Street CorpBought 33,700 shares on 5/16/2023Ownership: 0.255%Balyasny Asset Management L.P.Bought 19,369 shares on 5/16/2023Ownership: 0.031%Squarepoint Ops LLCBought 18,972 shares on 5/16/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions WVE Stock - Frequently Asked Questions Should I buy or sell Wave Life Sciences stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WVE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WVE, but not buy additional shares or sell existing shares. View WVE analyst ratings or view top-rated stocks. What is Wave Life Sciences' stock price forecast for 2023? 5 brokers have issued 12-month price objectives for Wave Life Sciences' shares. Their WVE share price forecasts range from $5.00 to $10.00. On average, they expect the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 67.9% from the stock's current price. View analysts price targets for WVE or view top-rated stocks among Wall Street analysts. How have WVE shares performed in 2023? Wave Life Sciences' stock was trading at $7.00 at the beginning of the year. Since then, WVE shares have decreased by 40.4% and is now trading at $4.17. View the best growth stocks for 2023 here. When is Wave Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our WVE earnings forecast. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) issued its quarterly earnings results on Wednesday, March, 22nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.05. The firm earned $1.24 million during the quarter, compared to analysts' expectations of $2.35 million. Wave Life Sciences had a negative trailing twelve-month return on equity of 1,038.84% and a negative net margin of 1,021.14%. What ETFs hold Wave Life Sciences' stock? ETFs with the largest weight of Wave Life Sciences (NASDAQ:WVE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and Invesco Nasdaq Biotechnology ETF (IBBQ). What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO? 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN). What is Wave Life Sciences' stock symbol? Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE." Who are Wave Life Sciences' major shareholders? Wave Life Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Maverick Capital Ltd. (6.71%), BlackRock Inc. (1.43%), FMR LLC (1.05%), Geode Capital Management LLC (0.70%), Bank of America Corp DE (0.58%) and Platinum Investment Management Ltd. (0.46%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP. View institutional ownership trends. How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Wave Life Sciences' stock price today? One share of WVE stock can currently be purchased for approximately $4.17. How much money does Wave Life Sciences make? Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $410.20 million and generates $3.65 million in revenue each year. The company earns $-161,820,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. How many employees does Wave Life Sciences have? The company employs 235 workers across the globe. How can I contact Wave Life Sciences? Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901. This page (NASDAQ:WVE) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.